Gut epithelial Interleukin-17 receptor A signaling can modulate distant tumors growth through microbial regulation
Menée à l'aide de lignées cellulaires, de modèles murins de tumeurs (pancréas, cerveau) ainsi que d'échantillons sanguins et d'échantillons tumoraux prélevés sur des patients atteints d'un adénocarcicome canalaire du pancréas, cette étude met en évidence un mécanisme par lequel la signalisation du récepteur A de l'interleukine IL-17 des cellules épithéliales de l'intestin peut moduler la croissance des tumeurs distantes via la régulation microbienne
Résumé en anglais
Microbes influence cancer initiation, progression and therapy responsiveness. IL-17 signaling contributes to gut barrier immunity by regulating microbes but also drives tumor growth. A knowledge gap remains regarding the influence of enteric IL-17-IL-17RA signaling and their microbial regulation on the behavior of distant tumors. We demonstrate that gut dysbiosis induced by systemic or gut epithelial deletion of IL-17RA induces growth of pancreatic and brain tumors due to excessive development of Th17, primary source of IL-17 in human and mouse pancreatic ductal adenocarcinoma, as well as B cells that circulate to distant tumors. Microbial dependent IL-17 signaling increases DUOX2 signaling in tumor cells. Inefficacy of pharmacological inhibition of IL-17RA is overcome with targeted microbial ablation that blocks the compensatory loop. These findings demonstrate the complexities of IL-17-IL-17RA signaling in different compartments and the relevance for accounting for its homeostatic host defense function during cancer therapy.
